



Corp. Off.:- 201, "The Summit Business Bay"
Behind Guru Nanak Petrol Pump,
Off Andheri Kurla Road, Andheri (E),
Mumbai - 400 093 (India)
Ph. : +91 22 69073100

12th November, 2021

BSE Limited

PhirozeJeejeebhoy Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G
BandraKurlaComplex
Bandra (E), Mumbai-400051

Kind Attn: General Manager-DCS

Scrip Code: **533543**

Kind Attn: Head- Listing

Symbol: **BROOKS**

Sub: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Dear Sirs,

This has in reference to the regulation mentioned above:

We hereby inform you that the Board of Directors at its meeting held today has, inter alia, approved the Unaudited Financial Results of the Company for the 2nd quarter and half yearly ended 30th September, 2021. The Audit Committee reviewed the Unaudited Financial Results at its meeting held earlier today which have been subjected to a limited review by the Statutory Auditors. The Statement of Standalone and Consolidated Unaudited Financial Results, Statement of Assets and Liabilities and Cash Flow Statement as at 30.09.2021 together with the Standalone and Consolidated Limited Review Report are attached.

This is for your information and record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**

(Jyoti Sancheti)



Company Secretary cum Compliance Officer

Membership No. F9639

Brooks Laboratories Limited

Regd Office: Village Kishaupura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net | Telefax No : +91 1795 236939

Statements of Unaudited Financial Results for the Quarter & Half year Ended 30th September, 2021

(Rs. In Lakhs)

Particulars	Standalone						Consolidated					
	Quarter Ended			Half year ended		Year Ended	Quarter Ended			Half year ended		Year Ended
	30-Sep-21	30-Jun-21	30-Sep-20	30-Sep-21	30-Sep-20	31-Mar-21	30-Sep-21	30-Jun-21	30-Sep-20	30-Sep-21	30-Sep-20	31-Mar-21
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income												
Revenue from operations	2,105.08	1,558.12	2,924.41	3,663.20	4,170.98	7,724.69	2,101.21	2,169.50	2,924.41	4,270.71	4,170.98	7,724.69
Other Income	34.43	92.25	52.30	126.68	63.47	98.79	55.57	70.23	52.30	125.80	63.47	73.55
Total income	2,139.51	1,650.37	2,976.71	3,789.88	4,234.45	7,823.48	2,156.78	2,239.73	2,976.71	4,396.51	4,234.45	7,798.24
2 Expenses												
(a) Cost of materials consumed	825.15	917.21	1,495.63	1,742.36	2,499.23	4,656.93	1,057.43	1,439.55	1,495.63	2,496.98	2,499.23	4,667.27
(b) Purchase of Stock in Trade	100.63	301.59	240.89	402.22	251.79	423.65	100.56	18.67	240.89	119.23	251.79	423.65
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	424.80	(350.96)	(55.80)	73.84	(309.48)	(333.58)	413.73	(102.05)	(55.80)	311.68	(309.48)	(333.58)
(d) Employees benefits expenses	319.39	292.21	362.68	611.60	669.68	1,436.83	458.03	412.28	362.68	870.31	669.68	1,436.83
(e) Finance Costs	12.39	18.13	80.28	30.52	157.92	309.41	75.18	76.11	80.28	151.29	157.92	309.84
(f) Depreciation and amortization expenses	35.01	35.74	170.83	70.75	368.41	709.29	173.51	178.20	170.83	351.71	368.41	714.33
(g) Other expenses	316.25	294.14	345.64	610.39	549.05	1,464.48	531.29	438.06	345.64	969.35	549.05	1,478.43
Total Expenses	2,033.62	1,508.06	2,640.15	3,541.68	4,186.60	8,667.01	2,809.74	2,460.82	2,640.15	5,270.56	4,186.60	8,696.77
3 Profit/(Loss) before Share of Profit / (Loss) of Associate, exceptional item and tax	105.89	142.31	336.56	248.20	47.85	(843.53)	(652.96)	(221.09)	336.56	(874.05)	47.85	(898.53)
4 Share of Profit / (Loss) of Associate	-	-	-	-	-	-	(12.59)	12.59	-	-	-	(0.80)
Profit/(Loss) before Exceptional item and tax	105.89	142.31	336.56	248.20	47.85	(843.53)	(665.55)	(208.50)	336.56	(874.05)	47.85	(899.33)
5 Exceptional items	-	-	-	-	-	-	-	-	-	-	-	-
6 Profit/(Loss) from ordinary activities before tax	105.89	142.31	336.56	248.20	47.85	(843.53)	(665.55)	(208.50)	336.56	(874.05)	47.85	(899.33)
7 Tax Expense:												
Deferred Tax Liability / (Assets)	-	-	-	-	-	-	(182.48)	(94.25)	-	(276.73)	-	322.99
MAT credit reversal	-	-	-	-	-	-	-	-	-	-	-	-
Tax of earlier years	-	-	-	-	-	715.23	-	-	-	-	-	715.23
8 Net Profit/(loss) after tax	105.89	142.31	336.56	248.20	47.85	(1,558.76)	(483.07)	(114.25)	336.56	(597.32)	47.85	(1,937.55)
9 Other Comprehensive Income												
Items That will not be reclassified into Profit or loss												
Actuarial Gain/ (Loss) on Defined Benefit Plans (Net of Tax)	(2.95)	(2.96)	(2.96)	(5.91)	(5.42)	10.79	(2.95)	(2.96)	(2.96)	(5.91)	(5.42)	10.79
10 Total Comprehensive income for the period	102.93	139.35	333.60	242.28	42.43	(1,547.97)	(486.03)	(117.21)	333.60	(603.24)	42.43	(1,926.76)
Net Profit attributable to												
Owners of equity	-	-	-	-	-	-	(483.06)	(114.26)	336.56	(597.32)	47.85	(1,937.55)
Non Controlling Interest	-	-	-	-	-	-	-	-	-	-	-	-
Total Comprehensive Income attributable to												
Owners of Equity	-	-	-	-	-	-	(486.02)	(117.22)	333.60	(603.24)	42.43	(1,926.76)
Non Controlling Interest	-	-	-	-	-	-	-	-	-	-	-	-
11 Paid-up equity share capital (Face Value of Rs. 10 each)	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28
12 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year.	3,950.76	3,950.76	7,371.32	3,950.76	7,371.32	7,371.32	5,444.56	5,444.56	-	5,444.56	-	-
13 Earnings per share (of Rs. 10/- each)												
(not annualised)												
(a) Basic	0.42	0.56	1.35	0.98	0.17	(6.31)	(1.97)	(0.47)	1.35	(2.44)	0.17	(7.84)
(b) Diluted	0.42	0.56	1.35	0.98	0.17	(6.31)	(1.97)	(0.47)	1.35	(2.44)	0.17	(7.84)

Brooks Laboratories Limited

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101


CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net | Telefax No : +91 1795 236939

Notes:

- 1 The above Financial Results of the Company have been reviewed by the Audit committee and approved by the Board of Directors at their respective meeting held on 12th November, 2021
- 2 The financial results have been prepared in accordance with Indian Accounting Standard ("Ind AS") prescribed under section 133 of the Companies Act 2013, read with relevent rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular Dated 5th July, 2016
- 3 The Consolidated Financial Results have been prepared in accordance with Ind AS 110 on "Consolidated Financial Statements" and Ind AS 28 on "Investments in Associates and Joint Ventures".
- 4 The Company operates in one reportable business segment i.e " Pharmaceuticals".
- 5 Figures of the previous reporting period has been reclassified/ regrouped wherever necessary to correspond with the figures of the current reporting period.

For and on Behalf of the Board



Rajesh Mahajan
Din : 02000634
Managing Director

Place: Baddi

Date : 12th November, 2021

Brooks Laboratories Limited

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net | Telefax No :+91 1795 236939

Statement of Assets & Liabilities as at 30th September, 2021

(Rs. In Lakhs)

	Particulars	Standalone		Consolidated	
		As at September 30, 2021 (Un audited)	As at March 31, 2021 (Audited)	As at September 30, 2021 (Un audited)	As at March 31, 2021 (Audited)
A	ASSETS				
1	Non Current Assets				
	(a) Property, Plant and Equipment	1,385.70	1,442.48	10,690.37	10,702.63
	(b) Capital work in progress	33.33	-	759.49	67.55
	(c) Right to use Assets	-	-	111.37	-
	(d) Intangible asset	45.07	53.38	58.29	66.65
	(e) Intangible asset under Development	2.15	2.15	2.15	2.15
	(f) Financial Assets				
	(i) Investments	4,680.54	4,680.54	2.00	2.00
	(ii) Other Financial Assets	105.04	132.85	148.97	132.85
	(g) Income Tax Assets (Net)	205.70	201.70	205.70	201.70
	(h) Other Non Current Assets	26.22	-	541.88	-
	Total Non - Current Assets	6,483.75	6,513.10	12,520.22	11,175.53
2	Current assets				
	(a) Inventories	1,522.16	1,237.87	2,470.09	2,360.31
	(b) Financial Assets				
	(i) Trade receivables	1,449.87	959.07	1,536.35	1,369.80
	(ii) Cash and Cash Equivalents	6.22	6.37	8.39	88.39
	(iii) Bank Balances other than cash & cash equivalents	91.98	81.99	113.22	81.99
	(iv) Other Financial Assets	127.70	43.68	127.70	43.68
	(c) Other Current Assets	230.18	205.46	686.32	835.97
	Total Current Assets	3,428.11	2,534.44	4,942.07	4,780.14
3	Non current asset held for sale	-	252.06	-	252.06
	TOTAL ASSETS	9,911.86	9,299.60	17,462.29	16,207.73
B	EQUITY AND LIABILITIES				
1	Equity				
	(a) Equity Share Capital	2,470.28	2,470.28	2,470.28	2,470.28
	(b) Other Equity	4,193.04	3,950.76	4,841.32	5,444.56
	Equity attributable to Owners of the Company	6,663.32	6,421.04	7,311.60	7,914.84
	Non-Controlling interests	-	-	-	-
	Total Equity	6,663.32	6,421.04	7,311.60	7,914.84
2	Liabilities				
	Non-current liabilities				
	(a) Financial Liabilities				
	(i) Borrowings	-	134.09	1,199.20	1,444.00
	(ii) Lease Liability	-	-	90.99	-
	(iii) Other Financial Liabilities	9.54	11.12	-	0.00
	(b) Deferred Tax Liabilities	-	-	46.27	322.99
	(b) Provisions	174.04	154.48	213.64	154.48
	Total Non - Current Liabilities	183.58	299.69	1,550.10	1,921.47
3	Current liabilities				
	(a) Financial Liabilities				
	(i) Borrowings	484.32	705.82	1,631.09	1,363.73
	(ii) Lease liability	-	-	16.77	-
	(iii) Trade Payables				
	- Due to micro and small enterprises	512.47	316.22	605.43	371.89
	- Due to Others	1,473.28	1,022.38	3,315.46	2,723.38
	(iii) Other Financial Liabilities	178.68	346.08	2,178.68	1,672.97
	(b) Other current liabilities	335.16	125.73	709.32	126.09
	(c) Provisions	81.05	62.64	143.84	113.34
	Total Current Liabilities	3,064.96	2,578.87	8,600.59	6,371.42
	TOTAL EQUITY AND LIABILITIES	9,911.86	9,299.60	17,462.29	16,207.73

For Brooks Laboratories Limited



Rajesh Mahajan

Place : Baddi
Date : 12th November, 2021

Rajesh Mahajan
Din : 02000634
Managing Director

Brooks Laboratories Limited

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net | Telefax No : +91 1795 236939

Cash Flow Statement for the Half year ended 30th September, 2021

(Rs. In Lakhs)

Particulars	Standalone		Consolidated	
	Half year ended 30 September 2021	Year ended 31 March 2021	Half year ended 30 September 2021	Year ended 31 March 2021
	Un audited	Audited	Un audited	Audited
A. CASH FLOW FROM OPERATING ACTIVITIES				
Net (loss) / profit before tax	248.20	(843.53)	(874.05)	(899.33)
Adjustments for				
Depreciation and amortisation expense	70.75	709.29	351.71	714.33
Finance cost	30.52	309.41	151.29	309.84
Interest income	(2.13)	(16.95)	(2.20)	(16.95)
Remeasurement of Defined benefit obligations	(5.91)	10.79	(5.91)	10.79
Dividend from current investments	(0.30)	(0.30)	(0.30)	(0.30)
Provision for Doubtful Capital Advance	-	18.65	-	18.65
Profit on sale of asset	(28.98)	-	(28.98)	-
Loss on discarded asset	-	5.61	-	5.61
Provision for Expected credit loss	51.90	4.62	59.62	4.62
Unrealised Foreign Exchange Gain	4.73	(17.64)	4.73	(17.64)
Operating profit before working capital changes	368.77	179.95	(344.09)	129.62
Adjustments for changes in working capital:				
Decrease / (increase) in Trade Receivables	(593.67)	878.75	(226.17)	199.42
Decrease / (increase) in Inventories	(284.29)	(974.05)	(109.78)	(982.82)
Decrease / (increase) in Other Assets	(24.72)	228.60	149.65	(189.38)
Decrease / (increase) in Other Financial Assets	(20.87)	46.39	(84.02)	46.39
(Decrease) / Increase in Trade and Other Payables	647.15	(201.64)	825.71	473.76
(Decrease) / Increase in Other Financial Liabilities	(166.67)	154.38	505.70	1,154.38
(Decrease) / Increase in Other Liabilities	209.43	(18.38)	583.23	(16.81)
(Decrease) / Increase in Long term Provisions	19.56	17.99	59.16	33.15
(Decrease) / Increase in Short term Provisions	18.41	18.52	30.50	18.52
Cash generated from / (used in) operations	173.11	330.51	1,389.90	866.25
Direct taxes paid (net of refunds received)	(4.00)	(420.38)	(4.00)	(420.38)
Net cash (used in) / from generated from operating activities	169.10	(89.86)	1,385.89	445.87
B. CASH FLOW FROM INVESTING ACTIVITIES				
Purchase of property, plant and equipment (including capital work in progress and capital advances)	(47.94)	(117.16)	(1,052.95)	(561.38)
Proceeds from sale of property, plant and equipment	290.00	-	290.00	-
Capital Advance	(26.22)	-	(541.88)	-
Investment in Associate company	-	(0.80)	-	-
Investment in Subsidiary	-	(5.00)	-	-
Net (investments in)/ proceeds from bank deposits (having original maturity of more than three months)	(1.40)	31.18	(31.23)	31.18
Interest received	2.13	16.95	2.20	16.95
Dividend received	0.30	0.30	0.30	0.30
Net cash (used in) / generated from investing activities	216.86	(74.53)	(1,333.56)	(512.96)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds/ (Repayment) from borrowings (net)	(355.59)	452.98	22.56	438.13
Repayment of Lease Liabilities	-	(20.70)	(10.43)	(20.70)
Finance costs paid	(30.52)	(301.11)	(144.47)	(301.55)
Net cash (used in) / from financing activities	(386.11)	131.17	(132.34)	115.89
Net Increase / (decrease) in cash and cash equivalents	(0.15)	(33.22)	(80.01)	48.80
Cash and cash equivalents at the beginning of the year	6.37	39.59	88.39	39.59
Cash and cash equivalents at the end of the year	6.22	6.37	8.38	88.39

Place : Baddi

Date : 12th November, 2021

For and on Behalf of Board



Rajesh Mahajan
Din : 02000634
Managing Director

SGCO & Co. LLP

Chartered Accountants

Limited Review Report on Unaudited Standalone Financial Results of Brooks Laboratories Limited for the quarter and half year ended on September 30, 2021 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To,
The Board of Directors of
Brooks Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Brooks Laboratories Limited (The "Company"), for the quarter and half year ended on September 30, 2021. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S G C O & Co. LLP

Chartered Accountants

Firm's Registration No. 112081W/W100184



Suresh Murarka

Partner

Mem.No. 044739

UDIN : 21044739AAAATE3040



Place : Mumbai

Date : 12th November, 2021

4A, Kaledonia,
2nd Floor, Sahar Road,
Near Andheri Station,
Andheri (East),
Mumbai - 400 069

Tel. +91 22 6625 6363
Fax. +91 22 6625 6364
E-mail. Info@sgco.co.in
www.sgco.co.in

Mumbai • Delhi

SGCO & Co.LLP

Chartered Accountants

Limited Review Report on Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2021 of Brooks Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors of
Brooks Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Brooks Laboratories Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2021 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
- Brooks Laboratories Limited (Parent Company)
 - Brooks Steriscience Limited (Subsidiary Company)
 - Steribrooks Penems Private Limited (Associate Company)

4A, Kaledonia,
2nd Floor, Sahar Road,
Near Andheri Station,
Andheri (East),
Mumbai - 400 069

Tel. +91 22 6625 6363
Fax. +91 22 6625 6364
E-mail. info@sgco.co.in
www.sgco.co.in



SGCO & Co. LLP

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial results of one subsidiary vis Brooks Steriscience Limited included in the consolidated unaudited financial results, whose financial results reflect total assets of Rs. 17,462.29 lakhs as at September 30, 2021 and total revenues of Rs. 1,071.09 lakhs and Rs. 459.71, total net profit/(loss) after tax of (843.19) lakhs and Rs. (574.04) and total comprehensive income / loss of Rs (843.19) lakhs and Rs. (574.04) lakhs, for the quarter and half year ended September 30, 2021 respectively, and cash out flows (net) of Rs. 80.00 lakhs for the half year ended September 30, 2021, as considered in the consolidated unaudited financial results. These financial results have been reviewed by other auditor whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. The consolidated financial statements also includes the Group's share of net Loss of Rs. (12.59) lakhs and Rs. Nil lakhs for the quarter and half year ended September 30; 2021 respectively, as considered in the consolidated unaudited financial statements, in respect of one associate (Steribrooks Penems Private Limited) whose financial statement/ financial information/ financial results have not been limited reviewed and have been furnished to us by the Management.

Our conclusion on the Statement is not modified in respect of the above matters.

For S G C O & Co. LLP

Chartered Accountants

Firm Registration No. 112081W/W100184

Suresh Murarka

Partner

Mem.No. 044739

UDIN : 21044739AAAATD1932



Place : Mumbai

Date : 12th November, 2021